Novel therapies for relapsed/refractory mantle cell lymphoma
- 1 March 2018
- journal article
- research article
- Published by Elsevier BV in Best Practice & Research Clinical Haematology
- Vol. 31 (1), 105-113
- https://doi.org/10.1016/j.beha.2017.10.010
Abstract
No abstract availableKeywords
This publication has 77 references indexed in Scilit:
- Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosisLeukemia Research, 2013
- Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 studyThe Lancet Oncology, 2011
- Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemiaBritish Journal of Haematology, 2010
- Outcome of Deferred Initial Therapy in Mantle-Cell LymphomaJournal of Clinical Oncology, 2009
- Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE studyAnnals of Oncology, 2009
- Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004Cancer, 2008
- Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphomaBlood, 2008
- Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell LymphomaJournal of Clinical Oncology, 2006
- Key role of the p110δ isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110δ function in B cellsBlood, 2006
- NF-κB and cell-cycle regulation: the cyclin connectionCytokine & Growth Factor Reviews, 2001